Three Good Things

2022 ◽  
pp. 104-117
Author(s):  
Judy Ruth Williamson

Let us consider some good things that have happened before the year 2021 concludes: 1) On February 1, 2021, researchers at Children's Hospital of Philadelphia (CHOP) announced that the autism spectrum disorders may be caused by defects in the mitochondria of brain cells of the eye. The research continues. 2) In the year 2021, many people have adopted the term “on the spectrum” to refer to the many brain dysfunctions that can and cannot be named and diagnosed yet. 3) Yale University Child Study Center and The Jim Henson Institute have invited many experts from many fields of study together to discover what happens when spectrum and non-spectrum children and adults look at puppets. What are they looking at? What do they see? Why don't we already know what they see? Are we looking at the important things? The chapter will explore these questions and specifically learning and the impact of puppets further.

2018 ◽  
Vol 21 (4) ◽  
pp. 146-154 ◽  
Author(s):  
Amparo Díaz-Román ◽  
Junhua Zhang ◽  
Richard Delorme ◽  
Anita Beggiato ◽  
Samuele Cortese

BackgroundSleep problems are common and impairing in individuals with autism spectrum disorders (ASD). Evidence synthesis including both subjective (ie, measured with questionnaires) and objective (ie, quantified with neurophysiological tools) sleep alterations in youth with ASD is currently lacking.ObjectiveWe conducted a systematic review and meta-analysis of subjective and objective studies sleep studies in youth with ASD.MethodsWe searched the following electronic databases with no language, date or type of document restriction up to 23 May 2018: PubMed, PsycInfo, Embase+Embase Classic, Ovid Medline and Web of Knowledge. Random-effects models were used. Heterogeneity was assessed with Cochran’s Q and I2 statistics. Publication (small studies) bias was assessed with final plots and the Egger’s test. Study quality was evaluated with the Newcastle Ottawa Scale. Analyses were conducted using Review Manager and Comprehensive Meta-Analysis.FindingsFrom a pool of 3359 non-duplicate potentially relevant references, 47 datasets were included in the meta-analyses. Subjective and objective sleep outcome measures were extracted from 37 and 15 studies, respectively. Only five studies were based on comorbidity free, medication-naïve participants. Compared with typically developing controls, youth with ASD significantly differed in 10/14 subjective parameters and in 7/14 objective sleep parameters. The average quality score in the Newcastle-Ottawa Scale was 5.9/9.Discussion and clinical implicationsA number of subjective and, to a less extent, objective sleep alterations might characterise youth with ASD, but future studies should assess the impact of pharmacological treatment and psychiatric comorbidities.


2017 ◽  
Vol 15 (4) ◽  
pp. 57-60
Author(s):  
T.S. Kubasova

The State Darwin Museum has been carrying out work on the socio-cultural rehabilitation of people with disabilities with museum facilities for the many years. The museum is actively developing the direction on the complex adaptation for visitors with autism spectrum disorders.


2019 ◽  
Vol 24 (4) ◽  
pp. 744-755
Author(s):  
Olga A. Vazhenina ◽  
Lidiya K. Lobodenko

The authors investigate the process of humanization of society in relation to people with autism spectrum disorders and its relationship with the reception of problems of this category of population by society. The authors based on the descriptors of messages in social media published in the digital media space. The article reveals the relationship between the content of messages in social media, as well as the tools of this type of media and the overall degree of humanization of society at both social and political levels. The typological features of such a social media tool as a hashtag, when covering the problems of people with autism spectrum disorders, as well as the impact of these features on the reception of messages on this topic by both domestic and English-speaking users are noted.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Rumi Agarwal ◽  
Shanna L. Burke ◽  
Marlaina Maddux

Abstract The core symptoms and co-morbidities associated with autism spectrum disorders (ASD) affect daily living and quality of life. Existing pharmacological interventions are only able to attenuate some related symptoms but are unable to address the underlying etiologies associated with ASD. Anecdotal evidence, which claims benefit from the use of cannabis to treat symptoms among this population, has been gaining popularity as families seek solutions. This paper analyzed recent peer-reviewed literature to identify the current state of evidence regarding cannabis use for the ASD population. Systematic reviews, reports, and experimental studies were assessed to understand the current extent and nature of the evidence on the risks and benefits of cannabis use for ASD. At this time, three large-scale clinical trials are currently at varying stages of progress and publication of results. Only five small studies were identified that have specifically examined cannabis use in ASD. Given the sparse state of evidence directly assessed in this population, studies which examined effects of cannabis on shared pathological symptoms of ASD such as hyperactivity, sleep disorders, self-injury, anxiety, behavioral problems, and communication were also reviewed. Studies revealed mixed and inconclusive findings of cannabis effects for all conditions, except epilepsy. Adverse outcomes were also reported, which included severe psychosis, increased agitation, somnolence, decreased appetite, and irritability. In addition, a wide range of cannabis compositions and dosage were identified within the studies, which impact generalizability. There is currently insufficient evidence for cannabis use in ASD, which creates an urgent need for additional large-scale controlled studies to increase understanding of risks and benefits and also to examine the impact of “entourage effects.” This will support discussions of treatment options between health care providers and ASD patients and their families. Evidence may lead to a desired new line of treatment or prevent adverse outcomes from unsubstantiated use amongst families aiming for symptom reduction.


2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Hirokazu Kumazaki ◽  
Yuichiro Yoshikawa ◽  
Yuko Yoshimura ◽  
Takashi Ikeda ◽  
Chiaki Hasegawa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document